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block as selectively as possible the pathological mecha-
nisms responsible for the disease.
New specific targeted therapies are being developed 
for several immune mediated diseases. Several clini-
cal trials are being performed to assess the efficacy 
and safety of this approach. all of them, however, rely 
largely on the clinical assessment of the patients to eval-
uate the effect of treatment. an objective and reliable 
method to visualize directly the immune process under-
lying the individual disease would be valuable; specific 
diagnostic tests, furthermore, may allow the selection of 
patients to be treated.
inflammatory diseases are a heterogeneous class of diseases characterized by chronic inflammation of the 
target organ, often relapsing, invalidating and requir-
ing life-long treatment. The so-called “aseptic chronic 
inflammatory diseases” include: autoimmune diseases, 
graft rejection, sarcoidosis, vasculitis, atherosclerosis 
and some degenerative diseases. in these patients, it is 
very important to try and achieve specific immunosup-
pression to extinguish the immune process with the aim 
of halting the disease, preventing or delaying complica-
tions and avoiding disease relapse, reducing to a mini-
mum side effect by using specific immune therapies that 
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a B S T r a c T
Crohn’s disease is a chronic relapsing disease characterized by mucosal inflammation, lymphocytes infiltration and fibrotic strictures. Usually, 
the assessment of location, extension, inflammatory activity and severity of intestinal lesions is complex and invasive with endoscopic meth-
ods or histological and biochemical investigations. Thus, the diagnosis remains a challenge for the management of patients. nuclear medicine 
techniques, in particular hybrid and molecular imaging, might offer a valid option for the evaluation and determination of the prognosis of the 
disease. indeed, imaging methods provide a non-invasive, reproducible and quantitative analysis. an overview of the currently available multi-
modality imaging techniques in crohn’s disease are reviewed, with particular regard to positron-emission tomography/magnetic resonance and 
the choice of the best evaluation Score, explaining advantages and disadvantages of each one, with particular regard to their potential role for 
the assessment of disease activity and extent of inflammation in order to improve the diagnosis. We propose new interpretation criteria for PET/
Mr images.
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In CD, the detection of lymphocytes infiltrating the 
mucosa and sub-mucosa represents an important early 
marker of disease, together with the measurement of 
other serological/genetic/morphological/histological 
markers. As early as diagnosis can be made a specific 
early treatment can be started and the same markers can 
be often used for therapy follow-up. for histological ex-
amination, tissue specimens can be obtained from gut, 
although biopsies represent only a very minimal part of 
the gut and foci of disease could be present in parts of 
the gut not accessible to biopsy. Therefore, the oppor-
tunity to image gut inflammation, non-invasively, and 
disease activity is an important goal for nuclear medi-
cine and radiology.
in this review, the current available multimodality 
imaging techniques were summarized, including single 
photon emission/computed tomography (SPecT), 18f-
fdg positron emission tomography/computed tomog-
raphy (PeT/cT) and positron-emission tomography/
magnetic resonance (PeT/Mr), with the aim to im-
prove the diagnosis and staging of disease activity (fig-
ures 1, 2).
Recent ECCO/ESGAR guidelines
The recent implementation of radiologic technique 
and imaging modalities for assessment of iBd has re-
quired an updated consensus document between the 
european Society of gastrointestinal and abdominal 
radiology (eSgar) and the european crohn’s and 
colitis organisation (ecco) in collaboration with 
eanM experts, in order to establish the diagnostic role 
nowadays, nuclear medicine techniques are not often 
used for the diagnosis of chronic inflammatory diseases, 
but they do greatly contribute to the management and 
determination of the prognosis of the disease because of 
their high sensitivity. This is of paramount importance 
since, in most cases, therapeutic options are available 
and a prompt start to treatment may prevent disease or 
delay complications.
one of the most important steps in the study of au-
toimmune diseases has been the development of mo-
lecular nuclear medicine that, with the production of 
specific radiopharmaceuticals, has contributed to the 
identification of the immune process responsible for the 
individual disease. new molecular therapeutic agents 
provide to localize specifically target, block inflamma-
tory reactions, obtaining information on disease activ-
ity, but also on the nature of the process and can, there-
fore, decide which treatment to start, when to start it and 
when to stop it or modify it.
crohn’s disease (cd) is characterized by a chronic 
mononuclear cell infiltration of the intestinal wall and 
hypertrophy of local lymphoid tissues.1 immune erosion 
of the intestinal wall may lead to severe complications of 
the affected bowel, such as stenosis and ulceration, which 
may require surgical resection. in over 70% of patients, 
relapse of the disease is noted within 1 year after the in-
tervention. in the early relapse phase, symptoms are in-
frequent and non-specific and conventional barium X-ray 
examinations are negative. Since effective therapies are 
available, early diagnosis of relapse might allow prompt 
initiation of therapy to prevent the onset of complications 
and the need for further surgical resection.2
figure 1.—coronal 
slide of abdominal 
PeT/Mr in a patient 
with acute crohn’s 
disease showing ac-
tive disease in the 
jejunal bowel loop 




nal PeT/Mr in a 
patient with ileal 
crohn’s disease re-
lapse. The arrow 
clearly shows the 
presence of active 
disease in a segment 
of terminal ileum.
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reason why WBCs scintigraphy could also be applied 
in this specific clinical condition in particular in the 
optic of monitoring disease’s activity.6-10 for these 
patients WBCs scintigraphy allows the evaluation 
of areas of bowel that cannot be explored with colo-
noscopy and it could represent a non-invasive pro-
cedure not only for diagnosis but also for follow-up 
and therapy monitoring. That could be extremely im-
portant for the children. Planar images, however, are 
burdened by the physiologic visualization of bowel 
after three hours, in particular for 99mTc-hMPao, that 
can result in a false positive scan. Moreover, the poor 
spatial resolution, tissue attenuation and in particular 
the lack of anatomical landmarks that led to the in-
ability to correctly localize the pathological focus of 
uptake have always been the great disadvantages of 
planar images.
The fusion of functional information, provided by 
scintigraphic imaging, with anatomic detail, provided 
by a radiological device, could overcome these limita-
tions. With the advances in the field of technologies and 
the development of hybrid imaging, the way to make 
imaging has been widely transformed.11 hybrid imaging 
is characterized by the integration of radionuclide imag-
ing and a cT scan. These two modalities can be coregis-
tered or acquired separately and then fused a posteriori. 
in the second case, however, artefacts in the orientation 
and alignment of the images could negatively influence 
the result so this modality is strictly dependent by the 
ability of the operator. hybrid imaging offers several 
advantages over planar images in particular consider-
ing that it provides an accurate fusion of functional and 
anatomical data enabling to a precise localization of the 
suspicious foci in a single imaging session that does not 
require any change in patient position. This is extremely 
important in the optic of sparing time and in particular, 
for cd, if we consider the movements of the bowel and 
so it would be desirable to coregister the cT and the 
SPecT. The use of X-ray tube of cT scan, is important 
not only for the anatomical data but also for the attenu-
ation correction of images that improves the diagnostic 
accuracy.
The appeal to the combination of SPecT or a PeT 
and a CT-scan is nowadays exploited in several fields 
and it often represents an undeniable diagnostic tool in 
different diseases. In the specific clinical setting of CD, 
a SPecT/cT could improve the diagnostic accuracy of 
of each of them. in this consensus document, the role 
the currently available imaging modalities, magnetic 
resonance imaging (Mri), computed tomography (cT), 
ultra-sonography (uS), and nuclear medicine examina-
tions, including hybrid imaging, has been re-evaluated. 
The sensitivity in the assessment of small and large 
bowel stenotic and penetrating lesions, of upper gastro-
intestinal (gi) tract lesions, of the global bowel damage, 
the accuracy in monitoring the therapeutic response, the 
assessment of colonic inflammation and complications, 
of perianal disease and urogenital, liver and biliary tract 
complications, has been separately discussed and re-
ported for each modality, as well as the role for emer-
gency situations and postoperative setting, with special 
attention to Mri.
The ECCO-ESGAR document has further confirmed 
the well-known diagnostic accuracy of cT and uS, also 
outlining the relative pros and cons. certainly, uS has 
a more limited coverage and lower accuracy than Mri 
and cT in exploring the entire length of the small or 
large bowel. on the other hand, although cT is very ac-
curate for assessing the main features of iBd, repeated 
cT examinations may expose patients to an increased 
life-time radiation-induced cancer risk, particularly 
children and young adults. repeated controls in cd 
patients should be performed with radiation-free tech-
niques, such as uS and Mri.
nuclear medicine procedures, especially white blood 
cells (WBCs) scintigraphy, can be considered as an al-
ternative to cross-sectional imaging for evaluation of 
disease activity and extension or complications in spe-
cific situations, with the main limitation of the radiation 
exposure and the poor anatomic detail. PeT/cT prelim-
inary studies with FDG were poorly specific for inflam-
mation and for assessing disease activity. The document 
has also outlined that cT, uS and small bowel follow-
through (SBfT) are generally more available and less 
expensive than Mri and scintigraphy or hybrid imag-
ing.3-5
Hybrid imaging
Radiolabeled WBCs using both 111indium (111in)-
oxine or 99mTc-hMPao are the nuclear medicine gold 
standard to detect several inflammatory and infective 
diseases. The presence of WBCs in the inflamed in-
testinal mucosa is the hallmark of cd and it is the 
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garding the acquisition protocols, the best imaging time 
is still debated. The higher diagnostic accuracy seems 
to be obtained within 3 hours post injection 8 because 
the accumulation of radiolabeled autologous leuco-
cytes in inflamed mucosa is very high at this time point, 
however the presence of physiological visualization of 
bowel, expression of excretion of 99mTc-hMPao, can 
give false positive results. A “squat” view in addition to 
anterior and posterior views can be useful in some cases 
in order to distinguish bladder from bowel.7 li et al.7 in 
1992 compared 99mTc-hMPao and 111In labeled WBCs 
in a large cohort of patients affected by cd. They ac-
quired only planar images after 2 hours post injection 
with fixed counts. Using a five-point scale of uptake in 
order to evaluate the inflammatory activity, comparing 
the bowel uptake with bone marrow and spleen, they 
found similar results in terms of sensitivity, specific-
ity, diagnostic accuracy, positive predictive value and 
negative predictive value between 99mTc and 111in (99mTc 
sensitivity 96%, specificity 97%, accuracy 97%, PPV 
97%; nPV 96%. 111In sensitivity 96%, specificity 97%, 
accuracy 97%, PPV 98%, nPV 96%). Becker et al. ob-
tained similar findings reporting a sensitivity of 96%, 
a specificity of 97% and a diagnostic accuracy of 98% 
in discriminating inactive from active inflammation 
in bowel segments.19, 20 aydin et al. performed WBCs 
scan at three-time point (1, 2 and 4 hours post injection) 
and they found better results after two hours. This time 
point seems to represent a good compromise between 
image quality and the risk to have false positive re-
sults.21 Some other authors explore the utility of SPecT 
in the quantification of inflammatory bowel activity ex-
pressed as a fraction of bone marrow uptake (SPecT 
Score) comparing these data with colonoscopy or sur-
gery. They found a correlation between SPecT Score 
and cd activity index (cdai), biochemical indexes of 
flogosis 22 and clinical parameters.23
as previously described, the limitations of planar im-
ages can be overcome by the integration with SPecT, 
or better with SPecT/cT, in order to improve the diag-
nostic performance of WBCs scan. Several papers are 
available in literature on the possible role of SPecT 
and SPecT/cT 20-25 in the evaluation of iBd report-
ing promising results. The added value of SPecT and 
SPecT/cT over planar images, include a more detailed 
visualization of the lesions and a better localization in 
the segments of bowel as summarized in Table i.22-28, 30
planar images acquired with WBCs scan in particular 
considering the physiologic visualization of bowel after 
3 hours post injection that could be misinterpreted as 
pathologic uptake in a segment.
[18f]-fdg PeT is a non-invasive, three-dimensional 
imaging technique that exploits the higher uptake of 
fdg, a structural analogue of 2-deoxyglucose, by cells 
with active glucose metabolism such as tumor and in-
fectious cells. These cells, overexpressing different 
isotypes of glucose transporters (gluT), trap fdg by 
phosphorylation, producing a greater signal than back-
ground. The activity in the region of interest might be 
quantified using a standardized uptake value (SUV), 
based on the activity in the target tissue, the injected 
dose and the subject’s weight. as well as SPecT, also 
PeT may be integrated with cT, combining the physi-
ological accuracy and functional data of PeT and the 
anatomical information of cT in order to improve the 
spatial and temporal resolution, detection and provide 
attenuation correction of PeT.12-14
in cd setting, PeT/cT is revealed very useful and 
feasible to assess extent, location and inflammatory ac-
tivity in the bowel, especially when conventional im-
aging cannot be performed or severe disease cases or 
strictures in the bowel prevent a complete endoscopy. 
furthermore, PeT/cT might be of particular importance 
for pediatric use due to its easy administration of fdg, 
non-invasive and fast procedure to acquire images.15-17
recently the industries are developing new PeT to-
mographs integrated with a Mri that seem to represent 
the future in diagnosis and follow-up of this disease, 
especially for being radiation-free for cd patients who 
need repeated imaging sessions over time during chron-
ic disease.
SPECT/CT papers using radiolabeled WBC  
or mAb antigranulocytes
a meta-analysis performed by annovazzi et al. on 
120 papers published from 1984 to 2005 on 4388 pa-
tients revealed that autologous leukocytes labeled with 
both 99mTc and 111in show higher diagnostic accuracy 
compared with monoclonal antibodies, barium studies, 
ultrasound and cT.18 The sensitivity and specificity of 
WBC scan however depends on the acquisition pro-
tocols and by the activity of the disease. in quiescent 
phases this examination seems to be less sensitive. re-
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study between 99mTc-il2 and 99mTc-hMPao granulo-
cytes, in patients with inactive cd, the two radiophar-
maceuticals, in most cases, accumulated in different 
areas, indicating that they can detect different types of 
inflammation, namely the lymphocytic infiltration in in-
flamed areas and the granulocytic infiltration in infected 
areas due to mucosal damage.33 Both radiopharmaceu-
ticals were characterized by high negative predictive 
values, but 99mTc-il2 was also characterized by a bet-
ter correlation with time to relapse.34 The use of 99mTc-
anti-TNFα has also been tested in CD for therapy deci-
sion-making and biological therapy follow-up, but the 
uptake of this radiopharmaceutical in the gut wall has 
been shown to be minimal and not to correlate with the 
response to therapy.35 These radiopharmaceuticals high-
lights the importance of hybrid imaging (SPecT/cT) 
for the precise localization of affected areas.
other interesting possibilities that are being explored 
in cd, are the use of radiolabeled antibiotics for direct 
imaging of bacterial presence in the damaged gut mu-
cosa,36 or new radiopharmaceuticals for imaging endo-
thelial activation as an early marker of vascular inflam-
mation in cd.37
Role of [18F]-FDG PET/CT
Several groups have evaluated the use of PeT in cd, 
summarized in Table ii.38-55 A first study backs to 1999 
where Skehan et al.38 performed [18f]-fdg PeT in 25 
pediatric patients with suspected iBd, 15 of whom with 
cd, using endoscopy with biopsy and SBfT as refer-
ence standards. They found an overall sensitivity of 
Considering the complex labeling process of WBCs 
that requires qualified personnel, adequate laboratory 
and instrumentation and blood manipulation, some au-
thors explored the possible role of antigranulocyte an-
tibodies in alternative to WBC scintigraphy.26-29 Kerry 
et al., compared 99mTc-WBCs with 99mTc leukoscan, a 
monoclonal fab antibody fragment that recognizes spe-
cific glycoproteins on granulocyte surface, in 22 patients 
affected by iBd.26 Sensitivity and specificity of WBCs 
after 2 hours post injection was 87% and 86%, higher 
than leukoscan. The sensitivity of monoclonal antibod-
ies increases with time from injection and it reaches a 
maximum at 4 hours (73% for planar images and 87% 
for SPECT). The specificity decreases with time from 
100% after 2 hours to 57% after 4 hours for both planar 
and SPecT images suggesting to acquire leukoscan at 
an earlier time after injection in order to improve the 
specificity, however at this time point the sensitivity 
was very low (40%) because it very difficult to distin-
guish pathologic uptake from physiologic visualization 
of bowel at early phases. Stokkel et al. also compared 
WBC and Leukoscan in 6 patients with IBD showing 
only a slight intestinal uptake in 50% of patients and the 
site did not correspond to the ones seen at WBCs scans 
and at endoscopy.27
from this analysis emerges that data available in lit-
erature seem to support the use of WBCs scan also in 
this clinical condition whereas the utility of antigranu-
locyte scintigraphy for imaging iBd is very limited.26-29
Several studies have been published on the use of 
radiolabeled il2 in patients with cd for the detection 
of bowel-infiltrating lymphocytes.30-32 in a comparative 
Table I.—Radiopharmaceuticals used for SPECT imaging of CD.
ref. radiopharmaceutical Modality added value of hybrid over planar images
Biancone et al.24 99mTc-WBCs SPecT (2 h p.i.) SPecT provides a more detailed visualization of cd lesions 
than planar images. This technique provides a maybe better 
discrimination between bowel and bone marrow uptake, thus 
being particularly useful for assessing lesions in the pelvis
hillele e al.25 99m Tc-WBCs SPecT (1 h p.i.) SPecT improves inter-operator variability and provides a correct of 
the extent of active disease
Weldon et al.22, 23 99m Tc-WBCs SPecT (1.5-2 h p.i.) Provides non-invasive quantification of bowel activity in both large 
and small bowel
Mota et al.26 99m Tc-WBCs SPecT (30 min-2 h p.i.) Could be useful to determine inflammatory activity in asymptomatic 
patients
filippi et al.27 99m Tc-WBCs SPecT/cT (na) Provides better anatomic detail in pelvic region useful for the 
detection of perianal fistula.
Kerry et al.28 99m Tc WBCs vs. 99mTc leukoScan SPecT (4 h p.i.) Improves both sensitivity and specificity. However, 99mTc 
leukoScan is not useful for imaging iBd
charron et al.30 99m Tc leukoScan SPecT (2-4 h p.i.) improves sensitivity
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Table II.—Radiopharmaceuticals used for PET imaging of CD.
ref Modality advantages disadvantages radiological burden issue
lemberg et al.39 PeT useful diagnostic adjunct to endoscopy, no 
bowel preparation, low radiation exposure, 
non-invasive
Low specificity, small group 
of patients
1.3 mSv with PeT compared 
with an estimated 20 mSv 
with small bowel study
Loffler et al.40 PeT fast, non-invasive, low radiation exposure, 
semi-quantitative analysis, high sensitivity
na effective dose: 3-7 mSv for 
children
Skehan et al.38 PeT useful technique for the detection of 
intestinal inflammation in children, adjunct 
to colonoscopy and barium studies
na Single patient effective dose: 
1.3 mSv
holtmann et al.41 PeT vs. hydro-Mri 
vs. colonoscopy
High sensitivity and specificity, 
complementary to colonoscopy for 
stenoses identification, non-invasive
Small group of patients, 
limited comparison with 
endoscopic data in some 
studies
Better combine PeT and 
Mri than cT because its 
significant radiation exposure
neurath et al.42 PeT vs. hydro-Mri 
vs. gaB
higher sensitivity than Mri and gaB and 
same good specificity, non-invasive
na na
Berthold et al.43 PeT vs. PeT/cT cT additional anatomical information no description of negative 
predictive value
The exposure of a PeT-cT is 
not higher than of a PeT-scan 
(estimated 3-7 mSv)
Bettenworth et al.44 PeT/cT non-invasive glucose uptake quite 
variable, pathologic 
findings not always 
differentiable
injected fdg activities and 
x-ray radiation doses of the 
cT scanner were reduced to 
the necessary minimum
Jacene et al.46 PeT/cT Sensitive qualitative analysis, correlation 
with histology
Small group of patients na
lapp et al.47 PeT/cT clinically useful in suspected and known cd 
patients for clinical decision-making
Small group of patients na
louis et al.48 PeT/cT High sensitivity, good specificity, good 
correlation with clinical and biological 
parameters
higher radiation exposure 
than Mri
10 mSv (0.1 mSv for the cT 
scout view, 4.5 mSv for the 
cT, and 5.7 mSv for the 
18f-fdg study) not allowed 
a frequent use
Meisner et al.49 PeT/cT cT essential for accurate cd analysis, non-
invasive
Small group of patients na
russo et al.51 PeT/cT correlation with clinicopathological 
markers, high sensitivity and modest 
specificity, assessment of early 
pharmacodynamic response
false positive due to deeper 
bowel layers, small group 
of patients
Total radiation dose for both 
scans: 11.2 mSv, optimized to 
lowest radiation exposure
Saboury et al.50 PeT/cT correlation with clinical, endoscopic, and 
lab indices of disease activity, detection 
and characterization of the anatomic 
location and the degree of inflammation in 
the bowel
lack of follow-up scan, not 
included small intestine 
and extra-intestinal lesions, 
small group of patients
na
das et al.52 PeT/cT 
enteroclysis
high sensitivity and resolution, unique 
scanning session, low radiation exposure
nasal and abdominal 
discomfort, lack of an 
endoscopic evaluation of 
the small intestine, lack of 
follow-up
less radiation exposure than 
barium studies/enteroclysis 
(12 15 mSv: (BMfT/
enteroclysis 3 mSV and cT 
abdomen 10 mSV)




high sensitivity, no bowel preparation less sensitive than Mr-
enteroclysis in detecting 
strictures in the duodenum/
proximal jejunum
8 mSv (18fdg-PeT below 7 
mSv, low-dose cT ¼ 1 mSv), 
less than a barium enema (15 
mSv)
ahmadi et al.53 PeT/cT 
enterography
non-invasive, additive to cTe, less time-
consuming, no bowel preparation
Small group of patients 7 mci- 4 mSv, similar to the
radiation exposure from a small 
bowel series
groshar et al.54 PeT/cT 
enterography
reduced background activity, better 
definition
Small group of patients, 
only one radiological 
interpretation
na
Shyn et al.55 PeT/cT 
enterography vs. cT 
enterography
Therapy monitoring, anatomical 
characterization, correlation with 
histopathology grading of inflammation 
and serum c-reactive protein
Small group of patients Effective dose: for the first 4 
patients range 13.9-23.9 mSv; 
for the last 9 patients range 
6.5-11.5 mSv
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especially in those parts of the small bowel that are not 
accessible to endoscopy.
Many authors investigated on the role of [18f]-fdg 
PET/CT for the assessment of inflammation in adult and 
pediatric patients with cd, where the cT scan provided 
better anatomical details, improving the diagnostic ac-
curacy of PeT. after a preclinical study, Bettenworth et 
al.44 performed PeT/cT in 25 patients with histologi-
cally diagnosed crohn’s colitis. PeT/cT showed posi-
tive findings in 88% of extensive ulcerations, but only 
in 50% of superficial epithelial lesions, concluding that 
PeT/cT is a non-invasive and promising translational 
method, but the intestinal glucose uptake is variable 
and pathologic segments are always not distinguishable 
from regular ones. The same group compared [18f]-
fdg PeT/cT, Mr-enteroclysis and trans-abdominal 
ultrasound in order to evaluate the best non-invasive 
imaging method for the detection and differentiation 
of inflammatory and fibromatous stenosis in CD, using 
endoscopy and histology as reference standards. de-
tection and differentiation rates of three methods were 
not so different to consider them statistically signifi-
cant. however, a combination between trans-abdom-
inal ultrasound and PeT/cT or Mr-enteroclysis led 
to a 100% detection rate of strictures.45 Jacene et al.46 
preoperatively investigated the accuracy of PeT/cT in 
cd patient with obstructive symptoms in comparison 
to postoperative histopathological analyses of these le-
sions. findings showed that fdg is taken up by dif-
ferent lesions, including inflammatory lesions, fibrotic 
strictures and muscle hypertrophy. Thus, a qualitative 
PeT analysis is quite sensitive, but a semi-quantitative 
analysis could help the identification of patients with 
active inflammation, using the maximum lean standard-
ized uptake value (Sulmax). another group studied the 
clinical utility of PeT/cT in 7 patients, 4 of whom with 
cd, indicating PeT/cT as a useful imaging method in 
diagnosis, management and clinical decision-making of 
patient with known or suspected cd.47 The accuracy of 
PeT/cT has been demonstrated by louis et al.48 in a 
prospective study which includes 22 patients with ac-
tive cd. They found that PeT/cT detected 35 of 48 
endoscopically affected segments with a sensitivity and 
specificity of 72.9% and 55.3%, respectively. Further-
more, severe endoscopic lesions, such as deep ulcers 
and strictures, were detected by PeT/cT with 100% 
of sensitivity, suggesting a direct proportion between 
81%, specificity of 85% and, when colonoscopy was 
limited, PET localized further inflammatory areas in the 
proximal large bowel. authors concluded that PeT is 
a useful technique in children and it may be used an 
adjunct to colonoscopy and barium studies when they 
are unsuccessful. Several years later, the same group 
confirmed that PET identified active inflammatory dis-
ease in 81.5% of cd patients, according to endoscopic 
results. Therefore, it does not have to replace conven-
tional studies, but to be an alternative and further inves-
tigation, considering the significant radiation exposure 
as limiting factor too.39 Also Loffler et al.40 performed 
fdg-PeT in 23 pediatric patients, 17 of whom with 
CD, obtaining a sensitivity and specificity equal to 98% 
and 68% with histology as standard of reference, 92% 
and 65% with endoscopy as standard of reference, re-
spectively. They considered PeT as a fast, non-invasive 
imaging method with low radiation exposure that al-
lows the assessment of disease activity in children at an 
early stage.
another group evaluated the accuracy of fdg-PeT 
to assess inflammation non-invasively in 43 CD pa-
tients, considering ileocolonoscopy and hydromagnetic 
resonance imaging (hydro-Mri) as reference stan-
dards. results showed that PeT might be comparable 
to hydro-Mri for the assessment of the proximal ileum, 
complementary to colonoscopy to identify the nature of 
stenosis with high sensitivity and specificity, suggesting 
PeT as a promising non-invasive technique for clinical 
management of cd.41 The same group compared PeT 
to hydro-Mri and antigranulocyte scintigraphy (gaB) 
in 59 patients with active cd, 28 of whom colonoscopy 
was performed. PeT had the highest sensitivity (85%) 
than hydro-Mri (67%) and gaB (41%), while a speci-
ficity equal to 89% comparable to hydro-MRI (93%), 
but not to gaB (100%). authors concluded that PeT 
allowed the non-invasive detection of inflamed gut seg-
ments in CD with high sensitivity and specificity.42 a 
comparison between PeT and PeT/cT has been dem-
onstrated by Berthold et al.43 in 23 children and ado-
lescents, 19 of whom with cd, using endoscopy with 
biopsy and histology as gold standard. cT provided 
additional anatomical information, although in this 
study only PeT was able to locate the activity in the 
gut segments. however, fdg detected extra intestinal 
inflammation, contributing to diagnosis and to determi-
nate the extent and degree of high-grade inflammation, 
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ments as well as PET, confirmed by correlation between 
cTe Score and SuVmax, suggesting a similar sensitivity 
of both imaging method and PeT may provide addition-
al information to cTe diagnostic data, determining in-
flammation degrees in abnormal small bowel segments. 
also, groshar et al.54 performed [18f]-fdg PeT/cTe 
in 28 patients with known or suspected cd in order to 
correlate the cTe Score and SuVmax for the assessment 
of the grade and severity of inflammation in abnormal 
segments. results showed the detection of 85 abnor-
mal segments in 22 patients, while 6 subjects had no 
abnormal segments, with a good directly proportional 
correlation between SuVmax and cTe measurements of 
mural thickness and enhancement, concluding that Su-
Vmax might be a reliable parameter to quantify cd activ-
ity. finally, Shyn et al.55 compared [18f]-fdg PeT/cTe 
with cTe alone with the purpose of evaluating the diag-
nostic efficacy of two imaging methods in 13 patients 
with cd, measuring different parameters such as cTe 
Severity Score, SuVmax, simplified endoscopic Score, 
and clinical parameters correlated with pathology in-
flammation grade. In 3 patients, PET detected active 
inflammation and an enterocolonic fistula, not revealed 
by cTe alone. Then, SuVmax was strongly correlated 
to disease activity, suggesting that PeT/cTe might im-
prove the detection and grading of active inflammation 
in cd patients.
PET/MR in IBD advantages and disadvantages
hybrid PeT/Mr scanners are the most advanced, 
clinically approved devices available for in-vivo diag-
nostic imaging. They acquire simultaneously (coacqui-
sition) or sequentially metabolic data from PeT and 
functional and morphologic information from Mr.56, 57
in the setting of coacquisition, the PeT and Mr com-
ponents of this hybrid technology simultaneously im-
age the same body region, allowing a nearly complete 
spatial and temporal matching of PeT and Mr data. 
This spatial and temporal matching is not achievable by 
sequential PeT/Mr scanners neither by PeT/cT, with 
the latter being limited by the necessarily asynchronous 
acquisition of the PeT events and the cT data.56
The matching of the PeT and Mr data translates into 
the possibility of exploring a queried lesion, for example 
a thickened bowel loop, with a large array of PeT and 
functional Mr (fMr) biomarkers that include, among 
sensitivity and significant endoscopic lesions. Globally, 
PeT/cT Score well correlated with clinical parameters, 
endoscopy and biological activity of cd. also, Meisner 
et al.49 conducted a pilot study using PeT/cT for the 
assessment of disease activity in 12 patients with iBd, 
7 of whom with cd. results showed that PeT/cT was 
positive in 59.4% of analyzed regions with 81.3% of 
correlation between PeT activity and clinical disease 
activity, demonstrating PeT as a non-invasive technique 
to identify active inflammatory regions in CD. The fea-
sibility and potential clinical utility of [18f]-fdg PeT/
cT for the assessment of cd activity was investigated 
in a study performed by Saboury et al.50 22 subjects un-
derwent PeT/cT followed by ileocolonoscopy in order 
to correlate the imaging scan results with clinical and 
endoscopic parameters. PeT/cT detected 15 additional 
segments compared to those visualized by endoscopy 
and all global PET parameters were significantly cor-
related to standard clinical Scores (cdai), allowing a 
new quantitative analysis of regional and global cd ac-
tivity using PeT imaging too. recently, russo et al.51 
evaluated the role of [18f]-fdg PeT/cT as a marker of 
progression of inflammatory activity and its response to 
anti-Tnf therapy in 22 patients with cd. for PeT/cT, 
the sensitivity and specificity were respectively 88% 
and 70%, the SUV showed significant cross-sectional 
and longitudinal correlation with clinicopathological 
markers like c-reactive protein and harvey-Bradshaw 
Index. Authors concluded that their study is a first in-
vestigation to comprehend the role of [18f]-fdg PeT/
cT in the early pharmacodynamic response and it needs 
larger and further studies.
other authors studied the cd activity combining 
[18f]-fdg PeT with cT enteroclysis or cT enterogra-
phy (cTe). das et al.52 included in a prospective study 
17 patients, 9 of whom with cd, using PeT/cT entero-
clysis in order to obtain both morphological and func-
tional details. PeT/cT enteroclysis detected 50 seg-
ments of small and large intestine with a significantly 
higher detection rate than barium studies and colonos-
copy, respectively 16 and 17 segments. furthermore, 
this imaging technique detected also extra-intestinal ab-
normalities and differentiated the active form of disease 
from the fibrostenotic form, resulting as a non-invasive, 
feasible and promising technique. ahmadi et al.53 ex-
amined the role of combined [18f]-fdg PeT/cTe in ac-
tive CD. CTe identified 48 abnormal small bowel seg-



































































































































































































































































































































































































































































































































caTalano hyBrid iMaging in crohn’S diSeaSe
48 The QuarTerly Journal of nuclear Medicine and Molecular iMaging March 2018
atlas based methods; however, the problem has not been 
resolved yet.
another potential disadvantage of PeT/Mr, com-
pared to PeT/cT, is the lengthier acquisition time (23-
30 minutes for a crohn’s PeT/Mr protocol versus 
12-15 minutes for a crohn’s PeT/cT study), with Mr 
acquisition being the time limiting factor. however, to 
take advantage of the potentialities offered by PeT/Mr, 
neither PeT nor Mr quality must be compromised.
Most of the research efforts in clinical PeT/Mr have 
been deployed in neuroimaging and oncologic imaging. 
in selected indications, PeT/Mr has been proven ad-
vantageous over PeT/cT, and also over PeT and Mr 
performed separately. for example, it improves staging 
of central nervous system cancers, detection of satel-
lite brain lesions, residual disease, and evaluation of 
intra-tumoral heterogeneity.64-68 in oncologic body im-
aging PeT/Mr has been demonstrated to be superior to 
PeT/cT and also to Mr in several respects, including 
evaluation of liver, peritoneal, bone, and lymph node 
metastases, and whole body staging of different primary 
cancers; moreover, it can also provide insights into the 
tumor biology, as in the case of breast cancer.69-78
PeT/Mr has enormous potentialities also in the eval-
uation of cd. however, it has been rarely used in this 
disease, with only two research manuscripts available in 
the literature.42, 48, 79-81
PET/MR might increase the diagnostic confidence 
in assessing patients affected by crohn’s disease. it has 
been shown that Mr enterography, PeT/cTe, and PeT/
Mr enterography had similar accuracy in detecting ar-
eas affected by cd. however, PeT/Mr enterography 
provided additional clinically relevant information due 
to its increased accuracy in assessing extra-luminal 
manifestations of the disease, that were associated with 
higher need for stoma (P=0.022), and also distant local-
ization (P=0.002).80
PeT/Mr enterography was also useful in assessing 
the dominant nature of strictures. Strictures constitute 
one of the most important clinical challenges in cd. 
They occur in about 11% of patients at presentation, 
and their prevalence increases over time. Moreover, 
they represent a major cause of morbidity in cd.45, 82, 83
While several medical options are available for pre-
dominantly inflammatory strictures, the fibrotic ones 
need to be treated more invasively, by surgery or me-
chanical dilatation. This pivotal information, however, 
others, SuVmax, metabolic volume, apparent diffusion 
coefficient (ADC), volume transfer coefficient (Ktrans). 
This would be precluded, due to bowel peristalsis and 
patient movements, in the case of sequentially acquired 
PeT and Mr scans.
Secondarily PeT/Mr coacquisition may symbioti-
cally overcome some limitations of each modality taken 
apart. in fact, Mr provides anatomic information that 
may improve PET-based quantification; this on the 
other side might be employed for in vivo validation of 
several functional Mr techniques.58 Moreover, serially 
acquired high temporal resolution Mr data can track 
and quantitate patient motion allowing for Mr-assisted 
PeT motion correction with subsequent reduction in 
PeT related motion artefacts, noise, blurring, and in-
creased contrast.58, 59
another important advantage of PeT/Mr compared 
to PeT/cT is the reduced radiation burden to the patient. 
PeT/Mr allows a 20% reduction in radiation exposure 
compared to PeT/cT, when the cT component is used 
for attenuation correction only, or up to 60-73% in the 
case the cT part is employed both for attenuation correc-
tion and for producing diagnostic quality cT images.60, 61
The geometry of the PeT components of the PeT/
Mr scanners, with the resultant increased sensitivity 
in the center of the PET field of view (FOV), allows 
reducing activity to up to 30-50% of that required for 
comparable quality PeT from PeT/cT.62
Moreover, the lengthier times required to acquire Mr 
sequences might be used to prolong PeT acquisition, 
improving the quality of the PeT images and/or allow-
ing a lower activity. in a phantom study, increasing bed 
position time by a factor of 8, from 2 minutes to 16 min-
utes, allowed reducing to 1/8 (12.5%) the injected activ-
ity with PeT images displaying same signal to contrast 
ratio as those obtained from 100% activity while using 
2 minutes per bed position.63
a major disadvantage of PeT/Mr compared to PeT/
cT relies in its limits in quantifying the attenuation ex-
erted by body tissues on the gamma-rays. While in PET/
cT the density of the tissues, as measured by cT houn-
sfield units, may be used to compute the linear attenu-
ation correction (lac), this is not the case of PeT/Mr 
where the signal intensity of the tissue does not have 
any direct relations with the lac. Several techniques 
have been employed to address this issue, the most ef-
fective being tissue segmentation/decomposition and 
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The following coacquired PeT/Mr sequences were 
coacquired: coronal short time inversion recovery 
(STir), axial T2w half fourier acquisition single shot 
turbo spin echo (haSTe), coronal T1w dixon, axial dif-
fusion weighted imaging (DWI). The coacquisition of 
this part of the study is essential to ensure temporal and 
spatial matching of the Mr and PeT data. after comple-
tion of the above described coacquired sequences, the 
following stand-alone breath-hold Mr sequences were 
obtained: coronal T2w haSTe, axial T1w dual gradi-
ent echo (ge), dynamic contrast enhanced T1w volu-
metric interpolated breath hold examination (ViBe). 
data were sent to a dedicated workstation (SyngoVia, 
Siemens, erlangen, germany). PeT images alone, Mr 
images alone, and combined PeT/Mr images were ran-
domly presented and analyzed at least 4 weeks apart. 
for standing-alone PeT, PeT images were assessed in 
the coronal and axial plane. for standing alone Mr, 
coronal portal venous phase contrast enhanced ViBe, 
coronal STir and coronal T2 weighted haSTe were 
assessed. for the combined PeT/Mr assessment, coro-
nal and axial PeT images, coronal portal venous phase 
contrast enhanced ViBe, coronal STir and coronal T2 
weighted haSTe were assessed. Mr and PeT images 
were evaluated both before and after coregistration and 
fusion.
The investigators were not aware of the surgical de-
scription but they were informed of the diagnosis of cd 
and of the occurrence of subsequent surgery.
for the analysis, the gastrointestinal tract was divided 
into five segments: stomach plus duodenum, jejunum, 
proximal ileum, distal ileus, and colon. each segment 
was classified as acutely inflamed if it satisfied the fol-
lowing criteria, otherwise it was considered negative for 
acute inflammatory changes:
for PeT, focally increased fdg uptake with SuVmax 
>4.
for Mr, bowel wall enhancement, increased signal 
on T2 weighted/STir images, and brisk post contrast 
enhancement.
for combined PeT/Mr images, coexistence of 
SuVmax ≥4 with at least one of the MR criteria reported 
above.
on the basis of the above criteria of the 105 segments 
evaluated in 21 patients: 66/105 segments were called 
positive on PeT, 53/105 on Mr, and 55/105 on PeT/
Mr.
is not usually available to the clinicians, due to the lim-
its of current techniques, even in the case of endoscopic 
biopsy. Therefore, patients are usually treated conser-
vatively first, and in the case of failure, a surgical ap-
proach is pursued.45, 82, 83
in two very recent PeT/Mr studies focused on this 
very specific topic, with surgical pathology as standard 
of reference, it was found that PeT/Mr could be use-
ful to differentiate between fibrotic and inflammatory 
strictures.
PeT/Mr enterography was more accurate in detect-
ing fibrosis compared with PET/CTe (P=0.043) and 
with Mr enterography (P=0.024).80
among the different PeT/Mr biomarkers that were 
investigated, the best discriminator between fibrosis and 
active inflammation was the hybrid PET/MR enterogra-
phy biomarker adc*SuVmax, that at a cut-off of less 
than 3000, was associated with accuracy, sensitivity, 
and specificity of 71%, 67%, and 73%, respectively.81
due to the possibility to coacquire PeT and Mr, the 
technique may potentially benefit from the synergism 
between the extremely high sensitivity of PeT in de-
tecting active lesions (sensitivity 84.5-100%) and the 
superior anatomic layout, high signal to noise ratio, and 
functional information provided by Mr. The authors of 
the current study retrospectively investigated the per-
formance of PeT/Mr versus PeT alone and versus Mr 
alone in assessing active inflammation in CD patients. 
of 43 consecutive patients who had undergone PeT/
Mr for cd between december 2012 and July 2016, 32 
patients underwent abdominal surgery within 8 weeks 
from the PeT/Mr. at the time of the study, operative 
surgical records were available for 21 of them and they 
constituted our study population.
Patients fasted for at least 6 hours before PeT/Mr 
acquisition. Two hours before scanning they were asked 
to start drinking at least two liters of a negative poly-
ethylene-glycol based oral contrast solution. Between 
80 and 90 minutes before acquisition, fdg at a 40% 
activity of that suggested by eanM guidelines was in-
jected. Finally, five minutes before the start of the PET/
Mr acquisition, 20 mg of Joscine n-butilbromure were 
injected intravenously. Scans were acquired with a si-
multaneous PeT/Mr scanner (mMr, Siemens, erlan-
gen, germany) starting from mid-thighs upward to the 
diaphragm. Two body coils (12 channels) were com-
bined to cover the entire abdomen.



































































































































































































































































































































































































































































































































caTalano hyBrid iMaging in crohn’S diSeaSe
50 The QuarTerly Journal of nuclear Medicine and Molecular iMaging March 2018
thickening, increased mesenteric vascularity or comb 
sign, mucosa ulcerations, increased local lymph nodes 
number-enhancement, intestinal complications. dis-
ease length) have been successfully correlated to bio-
logical, endoscopic or histological indexes inflamma-
tion.86, 87, 89, 91, 92, 94, 95
By arranging and integrating these parameters, sev-
eral qualitative and quantitative Scores have been 
proposed, each one based on similar Mri parameters. 
Validated quantitative Mri activity Scores include the 
Maria and the clermont Score.
The Maria (Magnetic resonance index of activity) 
Score, proposed by rimola et al.,95 is based on the asso-
ciation of two morphologic parameters, i.e. wall thick-
ening, mucosa ulcerations, and 2 MRI specific param-
eters, wall edema (assessed on T2w images only) and 
relative contrast enhancement or rce (on T1w post gd 
images); on the basis of a logistic regression analysis, 
all these parameters are linked by a mathematic formu-
la, which is: 1.5*wall thickness + 0.02*rce + 5*edema 
+ 10*ulceration.
hardonneau et al.96 proposed the Clermont Score, 
very similar to the Maria, but substituting gadolini-
um injection with DWI (diffusion weighted imaging), 
by using the quantitative values of the adc map as an 
alternative to the the gd-injection. authors conclude 
that clermont Score (=1.646 × bowel thickness-1.321 
× adc+5.613 × edema+8.306 × ulceration+5.039) was 
highly correlated with the Maria (rho=0.99) in ileal 
cd, although not in colonic cd (rho <0.80).
caruso et al.97 recently compared the clermont Score 
with the SeS (Simple endoscopic Score) Mre assessed 
active ileal disease in 31 patients (56.3%). in this study, 
the Clermont Score significantly correlated with the 
Maria Score (r=0.91; P<0.0001) and the Simple en-
doscopic Score for cd (r=0.76; P<0.0001).98, 99
an activity Score only has been histologically vali-
dated thus far, although based on a limited number 
of patients,100 proposed by Steward et al.87 The study 
showed that mural thickness (coefficient 1.34 [95% 
CI: 0.36, 2.32], P=0.007) and T2 signal (coefficient 
0.90 [95% ci: 0.24, 2.04] P=0.06) are best predic-
tors of the histopathological acute inflammation Score 
(aiS=1.79+1.34*mural thickness+0.94*mural T2 
Score).
recently, three Mre-based indices have been corre-
lated: the Maria, the clermont and the london indi-
at surgery 59/105 segments were positive for active 
inflammation. The true positive segments (TP) were 
54 in PeT, 47 in Mr, 52 in PeT/Mr; the true negative 
(Tn) segments were 34 in PeT, 40 in Mr, and 43 in 
PeT/Mr; the false positive (fP) segments were in 12 
in PeT, 6 in Mr, and 3 in PeT/Mr; the false negative 
segments were 5 in PeT, 12 in Mr, and 7 in PeT/Mr.
Mcnemar Test, with a p value of 0.05, was used to 
assess for statistical significance.
Sensitivity was 91.5% for PeT, 80% for Mr, and 
88% for PET/MR. While PET was statistically signifi-
cant more sensitive than Mr (P=0.02), no statistically 
significant differences were found between the sensitiv-
ity of PeT and PeT/Mr (P=0.48) neither between that 
of Mr and PeT/Mr (P=0.08).
Specificity was 74% for PET, 87% for MR, and 93% 
for PET/MR. The higher specificity of MR and PET/
MR, compared to PET, was statistically significant 
(P=0.04 and P=0.01 respectively). no statistically sig-
nificant differences were found between specificity of 
Mr and that of PeT/Mr (P=0.37).
diagnostic accuracy was 84% per PeT, 83% for Mr, 
and 91% for PeT/Mr. The better accuracy achieved by 
PeT/Mr, compared to PeT and Mr, was statistically 
significant (P=0.02 and P=0.01 respectively), mean-
while no statistically significant differences were ob-
served between overall accuracy of PeT and Mr.
in conclusion PeT/Mr proved to be more accurate 
than PET alone and MR alone, and more specific than 
PeT alone. PeT proved to be more sensitive than Mr 
alone. Therefore, PeT/Mr might, while coupling the 
strengths of Mr and PeT, is capable to overcome some 
of their limitations and might improve the evaluation 
of active inflammatory changes in Crohn’s disease pa-
tients.
The recently published MR Scores in CD 
(MaRIA vs. Clermont Scores and criticisms)
MRI, due to its high sensitivity for tissue inflamma-
tion, has been increasingly used to assess CD inflam-
mation and activity during the last two decades.84-93 
Thus far, both MR-specific parameters (T1weigthed 
gd-enhancement and T2weighted signal of the intes-
tinal wall, T1-w pattern of gd-enhancement, T2 mes-
enteric fat signal, curves of gd-wall enhancement, 
DWI-ADC values) as well as morphologic ones (wall 
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experience of the radiologist on Mre and cd imaging.
interestingly, rimola et al.99 have recently proposed 
the characterization of both inflammation and fibrosis 
in cd lesions using Mri. To do this, they evaluated 
the already known unenhanced parameters of the Maria 
Score, (wall thickening, edema, ulcers) plus signal in-
tensity at submucosa at 70 seconds and 7 minutes after 
gadolinium injection, stenosis, and pattern of enhance-
ment in each phase of the dynamic study, and changes 
on this pattern over time. By adding those parameters, 
Mri was able to discriminate between mild-moderate 
and severe fibrosis deposition with a sensitivity of 0.94 
and a specificity of 0.89.
recently, three Mre-based indices have been corre-
lated: the Maria, the clermont and the london indi-
ces.92-94, 98, 100 according to the aa, the three indexes 
have an overall high accuracy. The Maria index has 
the best operational characteristics for detecting not 
only disease activity but also for grading severity, which 
supports its use in clinical studies and clinical practice. 
The clearmont has the advantage to be free from gad-
olinium injection. The london index was “somewhat 
better than the other two for classifying segments as ac-
tive or inactive”.
finally, a recent study from Pendsé et al.,100 suggest a 
possible use of DWI for a qualitative rather than quan-
titative evaluation of cd. The authors reported that “the 
quantitative measurement of adc in bowel is often dif-
ficult due to the relatively thin bowel wall, given the typ-
ical image slice thickness (normal bowel wall 1-2 mm, 
typical DWI slice thickness 5-8 mm). Bowel peristalsis 
during image acquisition introduces further error”.
in conclusion, an ideal Mri activity index Score still 
does not exist. The several available Scores are all valu-
able, some of them have been validated versus clinical 
and endoscopic cd activity Scores, although none has 
been fully validated with histopathological specimens.
Our proposed interpretation criteria for PET/MR
When reading PET/MR in CD patients, at first, we 
evaluate the coronal reconstructed PeT, coronal STir, 
and coronal portal venous phase contrast enhanced 
ViBe, before and after having been coregistered and 
fused with PeT. The assessment of this set of images 
is useful, in our experience, to rapidly identify poten-
tial segments of active disease, and grossly estimate the 
ces.92-95, 98 according to the authors, the Maria index 
has the best operational characteristics for detecting not 
only disease activity but also for grading severity, which 
supports its use in clinical studies and clinical practice.
Several Mri qualitative Scores for cd activity have 
been also proposed or published, as an alternative to 
quantitative ones.
Maccioni et al.101 firstly proposed, in 2010, a quali-
tative Mri Score for cd activity (Qual-Mri-cdaS) 
based on the analysis, at the level of the most active 
intestinal segment affected by cd, of 5 different pa-
rameters, each one Scored 1-3 (absent-low: 1; definitely 
present: 2; markedly present: 3) on T1- T2 w images. 
These parameters include both morphological and spe-
cific MR parameters, as wall thickening, number of lo-
cal enhanced lymph nodes, T2 weighted signal intensity 
of the wall, T2 weighted perivisceral fluid/fat edema, 
T1 weighted early (60 seconds) wall enhancement. The 
basic Score 84-99 was also corrected according to the 
extent of the disease and evidence of severe inflamma-
tory complications, thus obtaining a good correlation 
(Spearman Test) was performed between with the Bio-
logical activity (Ba) (r=0.75), with the cd endoscopic 
activity index (cdeiS) (r=0.86) and cd activity index 
(cdai) (r=0.75).
a similar Score was also proposed and validated by 
Prezzi et al.,94 the so-called london index or Mr en-
terography global Score (MegS). MegS represents 
the evolution of a Score proposed initially by Steward 
et al.,93 which included the sum of qualitative grades 
for segmental mural thickness, mural T2 signal (mural 
edema), mural contrast enhancement and perimural T2 
signal. In order to better reflect the global burden of dis-
ease (i.e. beyond point estimates of segmental activity), 
the Score was expanded to include segmental disease 
length, evaluation of colonic haustral loss and evalu-
ation of extra-enteric complications, such as enlarged 
mesenteric lymph nodes, abscesses and fistulae. MEGS 
has been validated prospectively against stool calpro-
tectin, blood c-reactive protein (crP) and the harvey-
Bradshaw index, with satisfactory results.
The advantages of qualitative indexes rely on the 
easier application and more comprehensive assessment 
of the disease extent and severity; the main limitation is 
the subjectivity of the evaluation.
undoubtedly, both, qualitative and quantitative 
Scores, to be correctly applied, strongly depend on the 
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